Volume 27, Issue 1 (Spring 2021)                   IJPCP 2021, 27(1): 48-63 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Saberi Zafarghandi M B, Eshrati S, Arezoomandan R, Farnia M, Mohammadi H, Vahed N, et al . Review, Documentation, Assessment of Treatment, and Harm Reduction Programs of Substance Use Disorder in Iranian Prisons. IJPCP 2021; 27 (1) :48-63
URL: http://ijpcp.iums.ac.ir/article-1-3167-en.html
1- Department of Addiction, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran. , saberi.mb@iums.ac.ir
2- Department of Addiction, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran.
3- Education and Research Office of Iranian Prisons Organization, Tehran, Iran.
4- Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.
Full-Text [PDF 6105 kb]   (1622 Downloads)     |   Abstract (HTML)  (7857 Views)
Full-Text:   (2506 Views)
1. Introduction
One of the major problems in prisons is the increased drug use. It is estimated that the number of People Who Use Drugs (PWUDs) in prisons is 70%. The risk of HIV transmission in prisons is also high since a significant percentage of PWUDs inject drugs. On the other hand, the frequency of high-risk behaviors in a prison can increase the likelihood of the spread of related diseases in society. Therefore, development of policies and treatment programs for reduction of drug-related harm in prisons are of great importance. In this regard, the health department of Iran’s Prisons, Security and Corrective Measures Organization has implemented programs since the late 1991 to improve the health of prisoners and reduce the risks for public health. One of the concerns of the relevant authorities is the documentation of harm reduction measures and their modification in accordance with the conditions of the prisons. The present study aims to assess the implementation of drug-related harm reduction programs in prisons of Iran and suggest solutions for their improvement.

2. Methods
This is a descriptive cross-sectional study conducted in three steps. First, library method was used to collect information from the documents available in the library of Iran’s Prisons, Security and Corrective Measures Organization. In the second step, performance indicators were extracted and two researcher-made checklists were designed. The face and content validity of the checklists were evaluated based on the opinions of a panel of experts. The third step included a field visit through a semi-structured interview with service providers, service recipients, and prison authorities involved in the implementation of treatment programs and measures for harm reduction.

3. Results
The harm reduction programs were implemented since 2001 with the Methadone Maintenance Treatment (MMT) program conducted as a pilot in Ghezel Hesar Prison. To date, the treatment and harm reduction programs have been implemented in the most Iranian prisons with two major programs including MMT and triangular clinic. Table 1 summarizes the performance indicators of harm reduction programs in provincial prisons of Iran.






As can be seen in Table 1, the coverage rate of programs especially MMT in all prisons was almost 100%. Half of the provinces had no waiting list for treatment, 27% had a considerable number of waiting lists and 23% had low to moderate number of waiting lists. There was shortages of space, staff and budget in all prisons, which was one of the serious barriers to providing services according to the standards of the Ministry of Health. Most of prisons in provinces provided post-release services except in three provinces of Semnan, Kurdistan and Qazvin. Inadequate post-release services were considered as a factor in returning to prison. There was no monitoring and evaluation of the programs in any provinces. One of its reasons was the impossibility of cooperating with other organizations, such as medical sciences universities, research centers, and researchers outside of the prison. Based on field evidence and previous experience, prison officials acknowledged that harm reduction and treatment services had reduced mortality (especially in the quarantine unit), overuse of drugs, self-harm, suicide attempts, and violence.

4. Discussion and Conclusion
The harm reduction programs in prisons of Iran included MMT, diagnosis and treatment of HIV, hepatitis and sexually transmitted diseases as well as psychological interventions and NA meetings. Filed study and interviews revealed the effectiveness of these programs and, despite the budget and staff shortages, they had not been stopped. The implementation of some programs such as vocational training and recreational programs, although were not a part of harm reduction programs, helped reduce harms in prisons. Separate monitoring and evaluation of each program is required. One of the barriers was difficulty in cooperating with organizations such as medical sciences universities. Establishing regular meetings and persuading provincial officials such as judges, and providing advocacy support to the programs are the most important strategies for the continuation of the programs. The main challenges facing these programs were weakness in providing post-release services, insufficient staff and budget, inability to carry out the programs in accordance with the standard protocols, and difficulty in persuading some authorities and judges in implementing these programs. Increasing post-release services, staff and budget, and organizing training courses for the personnel of prisons are recommended.

Ethical Considerations
Compliance with ethical guidelines

All ethical principles are considered in this article. The participants were informed about the purpose of the research and its implementation stages. They were also assured about the confidentiality of their information and were free to leave the study whenever they wished, and if desired, the research results would be available to them.

Funding
This study was supported by the Office of Education and Research of Prisons, Security and Corrective Measures Organization. 

Authors contributions
Data collection: Mohammad Bagher Saberi Zafarghandi, Reza Arezoomandan, Arash Javaheri, Neda Vahed, Hosein Mohammadi, & Samaneh Heidari; Conducting interview: Mohammad Bagher Saberi Zafarghandi, Reza Arezoomandan, Hosein Mohammadi, & Samaneh Heidari; Transcription of interviews: Neda Vahed, Samaneh Heidari, and Sahar Eshrati; Study design: Mohammad Bagher Saberi Zafarghandi, Reza Arezoomandan, Marziyeh Farnia, & Sahar Eshrati; Final approval: All authors.

Conflicts of interest
The commissioner of this study was the Prisons, Security and Corrective Measures Organization. The study would not have been possible without the cooperation of the Deputy for Research and the Health Department of the organization. Participation of affiliated members in compiling reports and preparing the article can be an example of conflicts of interest, although they just provided scientific and executive assistance and the final analysis was done without organizational bias.

Acknowledgements
The authors would like to express their gratitude to Dean and Vice-Chancellor for Education of the School of Behavioral Sciences and Mental Health, members of the Department of Addiction Studies, Iran University of Medical Sciences (Dr. Imran Mohammad Razaghi, Dr. Haddadi, Dr. Sabahi Kermani, Dr. Alavi, Dr. Mortazavi, Dr. Nazem for assistance in collecting data, and Dr. Shabazi and Dr. Jafar Bolhari for participation in the interview), and staffs of the Office of Education and Research of Prisons, Security and Corrective Measures Organization.

Refrences:
  1. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey. Drug and Alcohol Dependence. 2009; 105(1-2):83-8. [DOI:10.1016/j.drugalcdep.2009.06.015] [PMID] [PMCID]
  2. Blaauw E, Roesch R, Kerkhof A. Mental disorders in European prison systems: Arrangements for mentally disordered prisoners in the prison systems of 13 European countries. International Journal of Law and Psychiatry. 2000; 23(5-6):649-63. [DOI:10.1016/S0160-2527(00)00050-9]
  3. Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, Seddighi AA, et al. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. International Journal of Drug Policy. 2010; 21(3):167-72. [DOI:10.1016/j.drugpo.2009.03.001] [PMID]
  4. Huby RH. Life in prison: Perspectives of drug injectors. Deviant Behavior. 2000; 21(5):451-79. [DOI:10.1080/01639620050085843]
  5. Eshrati B, Asl RT, Dell CA, Afshar P, Millson PM, Kamali M, et al. Preventing HIV transmission among Iranian prisoners: initial support for providing education on the benefits of harm reduction practices. Harm Reduction Journal. 2008; 5(1):21. [DOI:10.1186/1477-7517-5-21] [PMID] [PMCID]
  6. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. Aids. 2005; 19(7):709-16. [DOI:10.1097/01.aids.0000166094.24069.72] [PMID]
  7. Organization WH. Multi-city study on drug injecting and risk of HIV infection: A report prepared on behalf of the WHO International Collaborative Group. Geneva: World Health Organization; 1994. https://apps.who.int/iris/bitstream/handle/10665/62037/WHO_PSA_94.4.pdf?sequence=1
  8. Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, Srirak N, et al. Drug use, increasing incarceration rates, and prison-associated HIV risks in Thailand. AIDS and Behavior. 2003; 7(2):153-61. [DOI:10.1023/a:1023946324822]
  9. Dolan K, Rutter S, Wodak AD. Prison‐based syringe exchange programmes: A review of international research and development. Addiction. 2003; 98(2):153-8. [DOI:10.1046/j.1360-0443.2003.00309.x] [PMID]
  10. Horton A. Heroin users: The need for improved treatment for incarcerated women. Social Work in Public Health. 2011; 26(2):176-88. [DOI:10.1080/19371910903182773] [PMID]
  11. Jacob J, Stöver H. The transfer of harm-reduction strategies into prisons: needle exchange programmes in two German prisons. International Journal of Drug Policy. 2000; 11(5):325-35. [DOI:10.1016/S0955-3959(00)00050-5]
  12. Koulierakis G, Gnardellis C, Agrafiotis D, Power KG. HIV risk behaviour correlates among injecting drug users in Greek prisons. Addiction. 2000; 95(8):1207-16. [DOI:10.1046/j.1360-0443.2000.95812077.x] [PMID]
  13. Onorato IM, McCray E, Branch FS. Prevalence of human immunodeficiency virus infection among patients attending tuberculosis clinics in the United States. Journal of Infectious Diseases. 1992; 165(1):87-92. [DOI:10.1093/infdis/165.1.87] [PMID]
  14. Roshanfekr P, Farnia M, Dejman M. The effectiveness of harm reduction programs in seven prisons of Iran. Iranian Journal of Public Health. 2013; 42(12):1430. [PMID]
  15. Pourahmad M, Javady A, Karimi I, Ataei B, Kassaeian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infectious Diseases in Clinical Practice. 2007; 15(6):368-72. [DOI:10.1097/IPC.0b013e318142ce16]
  16. Zafarghandi MBS, Jadidi M, Khalili N. Iran’s activities on prevention, treatment and harm reduction of drug abuse. International Journal of High Risk Behaviors & Addiction. 2015; 4(4):e59737. [DOI:10.5812/ijhrba.22863] [PMID] [PMCID]
  17. United Nations Office on Drugs and Crime. Evaluation of substance use treatment programs [Interbet]. 2015 [Updated 2015]. Available from: https://www.unodc.org/documents/islamicrepublicofiran/publications/1jan2015/Evaluation_of_Substance_Use_Treatment_Programmes-EN.pdf
  18. World Health Organization. Work book 4: process evaluation [Internet]. 2000 [Updated 2000]. Available from: https://apps.who.int/iris/bitstream/handle/10665/66584/WHO_MSD_MSB_00.2e.pdf;jsessionid=097876A1DA8895D0405B0A22E4D9F5C4?sequence=5
  19. Bayan Zadeh AS, Bolhari J, Atef Vahid MK, Nouri Ghasem Abadi R, Fatali Lavasani F, Karimi Kismi E. [The role of medication and psychological interventions in harm reduction of substance use in addicted prisoners (Persian)]. Iranian Journal of Psychiatry and Clinical Psychology. 2007; 14(55):47-38. http://rjms.iums.ac.ir/article-1-731-fa.pdf
  20. Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. International Journal of Drug Policy. 2010; 21(5):422-4. [DOI:10.1016/j.drugpo.2010.03.008] [PMID]
  21. Werb D, Wood E, Small W, Strathdee S, Li K, Montaner J, et al. Effects of police confiscation of illicit drugs and syringes among injection drug users in Vancouver. International Journal of Drug Policy. 2008; 19(4):332-8. [DOI:10.1016/j.drugpo.2007.08.004] [PMID] [PMCID]
  22. Shahbazi M, Farnia M, Rahmani K, Moradi G. Trend of HIV/AIDS prevalence and related interventions administered in prisons of Iran-13 years’ experience. Iranian Journal of Public Health. 2014; 43(4):471-9. [PMID] [PMCID]
  23. Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N. The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care‐led methadone maintenance service. Addiction. 2010; 105(4):732-9. [DOI:10.1111/j.1360-0443.2009.02856.x] [PMID]
  24. Grella CE, Rodriguez L. Motivation for treatment among women offenders in prison-based treatment and longitudinal outcomes among those who participate in community aftercare. Journal of Psychoactive Drugs. 2011; 43(sup1):58-67. [DOI:10.1080/02791072.2011.602275]
  25. Farnia M, Shahbazi M, Moradi G, Alizadeh S, Ebrahi B, Kalle M. [Evaluation of harm reduction programs in prisons from the attitude and viewpoint of Iranian prison staff (Persian)]. Journal of School of Public Health & Institute of Public Health Research. 2013; 11(1):29-44. http://sjsph.tums.ac.ir/article-1-5016-fa.html
  26. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biological Psychiatry. 2004; 56(10):793-802. [DOI:10.1016/j.biopsych.2004.06.037] [PMID]
  27. Acosta MC, Marsch LA, Xie H, Guarino H, Aponte-Melendez Y. A web-based behavior therapy program influences the association between cognitive functioning and retention and abstinence in clients receiving methadone maintenance treatment. Journal of Dual Diagnosis. 2012; 8(4):283-93. [DOI:10.1080/15504263.2012.723317] [PMID] [PMCID]
  28. Moradi AR, Emdadi A, Soori B, Mostafavi E. Prevalence of human immunodeficiency virus infection among injection drug users released from Jail. Addiction & Health. 2012; 4(3-4):151. [PMCID] [PMID]
  29. Ross M. Health and health promotion in prisons. Milton Park: Routledge; 2012. [DOI:10.4324/9780203083239]
  30. Hutton HE, Treisman GJ, Hunt WR, Fishman M, Kendig N, Swetz A, et al. HIV risk behaviors and their relationship to posttraumatic stress disorder among women prisoners. Psychiatric Services. 2001; 52(4):508-13. [DOI:10.1176/appi.ps.52.4.508] [PMID]
  31. Grinstead OA, Zack B, Faigeles B, Grossman N, Blea L. Reducing postrelease HIV risk among male prison inmates: A peer-led intervention. Criminal Justice and Behavior. 1999; 26(4):453-65. [DOI:10.1177%2F0093854899026004003]
  32. Kamarulzam an A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. The Lancet. 2016; 388(10049):1115-26. [DOI:10.1016/S0140-6736(16)30769-3]
  33. Gough E, Kempf MC, Graham L, Manzanero M, Hook EW, Bartolucci A, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: A systematic review and meta-analysis. BMC Public Health. 2010; 10(1):777. [DOI:10.1186/1471-2458-10-777] [PMID] [PMCID]
  34. Zafarghandi MB, Eshrati S, Vameghi M, Ranjbar H, Arezoomandan R, Clausen T, et al. Drug-related community issues and the required interventions in open drug scenes in Tehran, Iran: a qualitative study protocol. BMJ Open. 2019; 9(10):e030488. [DOI:10.1136/bmjopen-2019-030488] [PMID] [PMCID]
Type of Study: Original Research | Subject: Psychiatry and Psychology
Received: 2020/01/31 | Accepted: 2020/09/27 | Published: 2021/04/20

References
1. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug and alcohol dependence. 2009; 105(1-2):83-8. 10.1016/j.drugalcdep.2009.06.015 [DOI:10.1016/j.drugalcdep.2009.06.015] [PMID] [PMCID]
2. Blaauw E, Roesch R, Kerkhof A. Mental disorders in European prison systems: Arrangements for mentally disordered prisoners in the prison systems of 13 European countries. International Journal of Law and Psychiatry. 2000; 23(5-6):649-63. 10.1016/s0160-2527(00)00050-9 [DOI:10.1016/S0160-2527(00)00050-9]
3. Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, Seddighi A-A, et al. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. International Journal of Drug Policy. 2010; 21(3):167-72. 10.1016/j.drugpo.2009.03.001 [DOI:10.1016/j.drugpo.2009.03.001] [PMID]
4. Huby RH, Meg. Life in prison: perspectives of drug injectors. Deviant Behavior. 2000;21(5):451-79. [DOI:10.1080/01639620050085843]
5. Eshrati B, Asl RT, Dell CA, Afshar P, Millson PM, Kamali M, et al. Preventing HIV transmission among Iranian prisoners: initial support for providing education on the benefits of harm reduction practices. Harm Reduction Journal. 2008; 5(1):21. 10.1186/1477-7517-5-21 [DOI:10.1186/1477-7517-5-21] [PMID] [PMCID]
6. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. Aids. 2005; 19(7):709-16. 10.1097/01.aids.0000166094.24069.72 [DOI:10.1097/01.aids.0000166094.24069.72] [PMID]
7. Organization WH. Multi-city study on drug injecting and risk of HIV infection: a report prepared on behalf of the WHO International Collaborative Group. Geneva: World Health Organization, 1994.
8. Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, Srirak N, et al. Drug use, increasing incarceration rates, and prison-associated HIV risks in Thailand. AIDS and Behavior. 2003; 7(2):153-61. 10.1023/a:1023946324822
9. Dolan K, Rutter S, Wodak AD. Prison‐based syringe exchange programmes: a review of international research and development. Addiction. 2003; 98(2):153-8. 10.1046/j.13600443.2003.00309.x [DOI:10.1046/j.1360-0443.2003.00309.x] [PMID]
10. Horton A. Heroin users: The need for improved treatment for incarcerated women. Social Work in Public Health. 2011;26(2):176-88. 10.1080/19371910903182773 [DOI:10.1080/19371910903182773] [PMID]
11. Jacob J, Stöver H. The transfer of harm-reduction strategies into prisons: needle exchange programmes in two German prisons. International Journal of Drug Policy. 2000; 11(5):325-35. 10.1016/s0955-3959(00)00050-5 [DOI:10.1016/S0955-3959(00)00050-5]
12. Koulierakis G, Gnardellis C, Agrafiotis D, Power KG. HIV risk behaviour correlates among injecting drug users in Greek prisons. Addiction. 2000;95(8):1207-16. 10.1046/j.1360-0443.2000.95812077.x [DOI:10.1046/j.1360-0443.2000.95812077.x] [PMID]
13. Onorato IM, McCray E, Branch FS. Prevalence of human immunodeficiency virus infection among patients attending tuberculosis clinics in the United States. Journal of Infectious Diseases. 1992;165(1):87-92. [DOI:10.1093/infdis/165.1.87] [PMID]
14. Roshanfekr P, Farnia M, Dejman M. The effectiveness of harm reduction programs in seven prisons of Iran. Iranian journal of public health. 2013;42(12):1430. PMID: 26060645
15. Pourahmad M, Javady A, Karimi I, Ataei B, Kassaeian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infectious Diseases in Clinical Practice. 2007; 15(6):368-72. 10.1097/IPC.0b013e318142ce16 [DOI:10.1097/IPC.0b013e318142ce16]
16. Zafarghandi MBS, Jadidi M, Khalili N. Iran's activities on prevention, treatment and harm reduction of drug abuse. International journal of high risk behaviors & addiction. 2015;4(4). 10.5812/ijhrba.22863 [DOI:10.5812/ijhrba.22863] [PMID] [PMCID]
17. United Nations Office on Drugs and Crime. Evaluation of substance use treatment programs (2015).https://www.unodc.org/documents/islamicrepublicofiran/publications/1jan2015/Evaluation_of_Substance_Use_Treatment_Programmes-EN.pdf
18. World Health Organization. Work book 4: process evaluation (2000). https://apps.who.int/iris/bitstream/handle/10665/66584/WHO_MSD_MSB_00.2e.pdf;jsessionid=097876A1DA8895D0405B0A22E4D9F5C4?sequence=5
19. Bayan Zadeh A, Bolhari J, Atef Vahid MK, Nouri Ghasem Abadi R, Fatali Lavasani F, & Karimi Kismi E. The role of medication and psychological interventions in harm reduction of substance use in addicted prisoners. Iranian Journal of Psychiatry and Clinical Psychology. 2007; 14(55): 47-38.
20. Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. International Journal of Drug Policy. 2010;21(5):422-4. 10.1016/j.drugpo.2010.03.008 [DOI:10.1016/j.drugpo.2010.03.008] [PMID]
21. Werb D, Wood E, Small W, Strathdee S, Li K, Montaner J, et al. Effects of police confiscation of illicit drugs and syringes among injection drug users in Vancouver. International Journal of Drug Policy. 2008; 19(4):332-8. 10.1016/j.drugpo.2007.08.004 [DOI:10.1016/j.drugpo.2007.08.004] [PMID] [PMCID]
22. Shahbazi M, Farnia M, Rahmani K, Moradi G. Trend of HIV/AIDS prevalence and related interventions administered in prisons of Iran-13 years' experience. Iranian journal of public health. 2014;43(4):471. PMID: 26005657
23. Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N. The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care‐led methadone maintenance service. Addiction. 2010;105(4):732-9. 10.1111/j.1360-0443.2009.02856.x [DOI:10.1111/j.1360-0443.2009.02856.x] [PMID]
24. Moradi AR, Emdadi A, Soori B, Mostafavi E. Prevalence of Human Immunodeficiency Virus Infection among Injection Drug Users Released from Jail. Addiction & health. 2012; 4(3-4):151. PMID: 24494150
25. Farnia M, Shahbazi M, Moradi G, Alizadeh S, Ebrahi B, Kalle M. Evaluation of harm reduction programs in prisons from the attitude and viewpoint of Iranian prison staff. Journal of School of Public Health & Institute of Public Health Research. 2013;11(1). [in Persian]
26. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biological Psychiatry. 2004; 56(10):793-802. 10.1016/j.biopsych.2004.06.037 [DOI:10.1016/j.biopsych.2004.06.037] [PMID]
27. Acosta MC, Marsch LA, Xie H, Guarino H, Aponte-Melendez Y. A web-based behavior therapy program influences the association between cognitive functioning and retention and abstinence in clients receiving methadone maintenance treatment. Journal of dual diagnosis. 2012; 8(4):283-93. 10.1080/15504263.2012.723317 [DOI:10.1080/15504263.2012.723317] [PMID] [PMCID]
28. Emdadi A. Prevalence of Human Immunodeficiency Virus Infection among Injection Drug Users Released from Jail. Addiction and Health. [in Persian].
29. Ross M. Health and health promotion in prisons: Routledge; 2012. [DOI:10.4324/9780203083239]
30. Hutton HE, Treisman GJ, Hunt WR, Fishman M, Kendig N, Swetz A, et al. HIV risk behaviors and their relationship to posttraumatic stress disorder among women prisoners. Psychiatric Services. 2001; 52(4):508-13. 10.1176/appi.ps.52.4.508 [DOI:10.1176/appi.ps.52.4.508] [PMID]
31. Grinstead OA, Zack B, Faigeles B, Grossman N, Blea L. Reducing postrelease HIV risk among male prison inmates: A peer-led intervention. Criminal Justice and Behavior. 1999;26(4):453-65. https://doi.org/10.1177/0093854899026004003 [DOI:10.1177%2F0093854899026004003]
32. Kamarulzam an A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. The Lancet. 2016;388(10049):1115-26. 10.1016/S0140-6736(16)30769-3 [DOI:10.1016/S0140-6736(16)30769-3]
33. Gough E, Kempf MC, Graham L, Manzanero M, Hook EW, Bartolucci A, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health. 2010;10(1):777. doi: 10.1186/1471-2458-10-777 [DOI:10.1186/1471-2458-10-777] [PMID] [PMCID]
34. Zafarghandi MB, Eshrati S, Vameghi M, Ranjbar H, Arezoomandan R, Clausen T, Waal H. Drug-related community issues and the required interventions in open drug scenes in Tehran, Iran: a qualitative study protocol. BMJ open. 2019 Oct 1;9(10):e030488. http://dx.doi.org/10.1136/bmjopen-2019-030488 [DOI:10.1136/bmjopen-2019-030488] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Iranian Journal of Psychiatry and Clinical Psychology

Designed & Developed by : Yektaweb